<DOC>
	<DOCNO>NCT01974713</DOCNO>
	<brief_summary>Longitudinal cohort patient chronic kidney disease follow 3 kidney center Ontario . The goal determine whether rate renal disease progression affect inflammatory marker , FGF23 level , genetic polymorphism</brief_summary>
	<brief_title>Inflammatory Markers Adverse Outcomes Chronic Kidney Disease</brief_title>
	<detailed_description>This longitudinal cohort study follow 2500 prevalent Chronic Kidney Disease ( CKD ) patient care nephrologist 3 Southern Ontario Nephrology centre affiliate satellite centre estimate Glomerular Filtration Rate ( eGFR ) less 60 ml/min determine rate renal disease progression 36 month . All CKD patient older 18 year age may include study . This study analyze , 6 month serial measurement , conventional biochemical , hormonal metabolic parameter addition demographic , clinical status , medication blood urine sample patient . This study assess influence inflammation FGF23 genetic polymorphism may reflect process involve disease progression .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients refer nephrologist evaluation CKD currently see nephrologist , eGFR less 60 ml/min Patients erythropoietin treatment naive Transplant patient fail graft require nephrologists followup Patients currently receive RRT consent study Adults 18 year age old Functioning Organ transplant Life expectancy le 12 month Patients currently receive RRT likely initiate RRT within 6 month Patients unable contraindicate receive EPREXÂ® erythropoietin replacement therapy correction anemia relate CKD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>CKD progression</keyword>
	<keyword>Inflammation</keyword>
	<keyword>FGF23</keyword>
	<keyword>Genetic biomarkers</keyword>
</DOC>